The quinazoline DBeQ is an ATP competitive VCP inhibitor, whereas NMS-873 is a non-ATP-competitive allosteric inhibitor of VCP.1, 27, 42 Both inhibitors rapidly turn off VCP enzymatic activity and thereby avoid potential limitations of genetic targeting related to slow or incomplete depletion of the abundant VCP.1, 57 As expected, a 24-h treatment with bortezomib effectively killed the OPM-2, Roswell Park Memorial Institute (RPMI)-8226, and H929 MM cell lines at an IC50 of ~5–10 nM (Figure 1a and Supplementary Table S1). This evidence concerns the gene VCP and Miyoshi myopathy.